Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C53H90O22 |
Molecular Weight | 1079.2685 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@]8([H])OC[C@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=NODILNFGTFIURN-GZPRDHCNSA-N
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)36(60)28(20-55)71-48)74-46-42(66)38(62)35(59)27(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26-,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-,46-,47-,48-,50-,51+,52+,53-/m0/s1
Molecular Formula | C53H90O22 |
Molecular Weight | 1079.2685 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb2/
https://www.ncbi.nlm.nih.gov/pubmed/23717160
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb2/
https://www.ncbi.nlm.nih.gov/pubmed/23717160
Ginsenoside C is a triterpene saponin originally found in species of Panax (ginseng) that exhibits anti-osteoporotic, antioxidative, antiviral, anti-hyperlipidemic, anti-metastatic, anti-angiogenic, and anticancer chemotherapeutic activities. In vivo, ginsenoside C decreases levels of malondialdehyde and increases levels of glutathione, improving bone microarchitecture and bone mineral density. In other animal models, this compound decreases virus titers and protects against infection of hemagglutinating virus of Japan. In adipocytes, ginsenoside C decreases levels of cholesterol and triglycerides and increases expression of SREBP. In uterine endometrial cancer cells, ginsenoside C decrease expression of matrix metalloproteinase 2 (MMP2), suppressive cellular invasion; this compound also inhibits neovascularization and tumor growth in animal models of melanoma. Ginsenoside C is a component of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:
• Alzheimer's disease. Evidence shows that taking Panax ginseng root daily for 12 weeks can improve mental performance in people with Alzheimer's disease.
• Lung disease called chronic obstructive pulmonary disease (COPD). Taking Panax ginseng by mouth seems to improve lung function and some symptoms of COPD.
• Mental function. Taking Panax ginseng by mouth might improve abstract thinking, mental arithmetic skills, and reaction times in healthy, middle-aged people but not in young adults. Panax ginseng alone does not seem to improve memory. But there is some evidence that a combination of Panax ginseng and ginkgo leaf extract can improve memory in otherwise healthy people between the ages of 38 and 66.
• Erectile dysfunction (ED). Taking Panax ginseng by mouth seems to improve sexual function in men with erectile dysfunction.
• Flu. Taking a specific Panax ginseng by mouth appears to reduce the risk of getting a cold or the flu. But, taking Panax ginseng does not seem to reduce flu symptoms or the length of the illness.
• Multiple sclerosis-related fatigue. Taking Panax ginseng daily for 3 months reduces feelings of tiredness and improves quality of life in females with MS.
• Premature ejaculation. Applying a cream containing Panax ginseng, angelica root, Cistanches deserticola, Zanthoxyl species, torlidis seed, clover flower, asiasari root, cinnamon bark, and toad venom (SS Cream) to the penis one hour before intercourse and washing off immediately before intercourse seems to help prevent premature ejaculation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26981165 |
|||
Target ID: GO:0050432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25352764 |
|||
Target ID: GO:0045453 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24933344 |
|||
Target ID: CHEMBL2096907 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02204826
KRG extract contained 1.62mg/g Ginsenoside C, as well as ginsenoside-Rb1: 4.26mg/g, -B2: 1.71 mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules (500 mg/dose) were taken daily for 12 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24933344
Treatment of 0.1 to 10uM Ginsenoside C promoted the proliferation of MC3T3-E1 cells, improved alkaline phosphatase (ALP) expression, elevated calcium mineralization and mRNA expressions of Alp, Col1a1, osteocalcin (Ocn) and osteopontin (Opn) against oxidative damage induced by H2O2.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:08:23 GMT 2023
by
admin
on
Sat Dec 16 03:08:23 GMT 2023
|
Record UNII |
N219O0L31C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
308878
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
77151
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
234-251-4
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
DB06748
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
77152
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
6917976
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
11021-13-9
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
DTXSID00911541
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY | |||
|
N219O0L31C
Created by
admin on Sat Dec 16 03:08:24 GMT 2023 , Edited by admin on Sat Dec 16 03:08:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|